Agenus Inc. (AGEN) Stock: Here’s What’s Happening

0

Agenus Inc. (AGEN) is making a move down in the market today. The stock, focused on the biotech space, is presently priced at $2.79 after tumbling 0.00% so far in today’s session. As it relates to biotechnology stocks, there are quite a few factors that have the ability to cause movement in the market. One of the most common is news. Here are the most recent stories relating to AGEN:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Aug-15-19 06:51PM Edited Transcript of AGEN earnings conference call or presentation 8-Aug-19 12:30pm GMT
Aug-10-19 01:43AM Agenus Inc (AGEN) Q2 2019 Earnings Call Transcript
Aug-09-19 11:09AM Agenus (AGEN) Q2 Earnings Miss Estimates, Revenues Beat
Aug-08-19 09:35AM Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates
07:30AM Agenus Reports Second Quarter 2019 Financial Results and Provides Corporate Update

However, any time investors are making an investing decision, investors should look at far more than just news, this is especially the case in the highly speculative biotechnology space. Here’s what’s happening in regard to Agenus Inc..

Recent Movement From AGEN

While a move down on a single session, like the fall that we’re seeing from Agenus Inc. may cause fear in some investors, a single session decline by itself should not be the reason for a decision to, or not to, invest in a stock. It is generally smart to look at trends beyond a single trading day. In the case of AGEN, here are the returns that we’ve seen:

  • Past 5 Trading Sessions – Throughout the last week, AGEN has seen a price change in the amount of -1.41%.
  • Monthly – The return from Agenus Inc. over the last 30 days works out to 21.30%.
  • Past Quarter – In the past quarter, the company has generated a return of -2.45%
  • Past Six Months – Over the past 6 months, we’ve seen a performance that equates to -6.38% from the stock.
  • This Year So Far – Since the the first trading session of this year AGEN has resulted in a return on investment of 17.23%.
  • Annually – Lastly, in the last full year, we’ve seen a change in the amount of 35.44% from AGEN. Over this period of time, the stock has sold at a high of -28.09% and a low of 81.17%.

Ratios To Watch

Looking at a few key ratios associated with a company can give traders an understanding of how dangerous and/or potentially profitable a stock pick might be. Here are some of the important ratios to look at when looking at AGEN.

Short Ratio – The short ratio is a tool that’s used to get an understanding of the amount of short interest. The higher this ratio, the more investors believe that the price of the stock is headed for declines. In general, biotechnology stocks tend to come with a higher short ratio. However, we tend to see quite a few short squeezes in the sector. Nonetheless, as it relates to Agenus Inc., it’s short ratio clocks in at 12.69.

Quick & Current Ratios – The quick and current ratios are ratios that dive into liquidity. Essentially, they measure If a company is able to pay for its debts as they mature based on current assets or quick assets. Because many biotech many companies are reliant on continued investor support, the current and quick ratios can look upsetting. Nonetheless, several gems in the biotech space come with strong current and quick ratios. When it comes to AGEN, the quick and current ratios come to 1.10 and 1.10 respectively.  

Book To Share Value – The book to share value compares the the share price to the book value of assets owned by the company. In this particular case, the book to share value ratio is -1.17.

Cash To Share Value – Finally, the cash to share value ratio compares the amount of cash the company has on hand to the price of shares. Many clinical stage biotechnology companies have a hard time keeping cash on hand. So, if you’re considering an investment in a stock in the biotechnology industry, this is an important ratio to look into. In this case, the cash to share value ratio is 0.

What Analysts Think About Agenus Inc.

Although it’s not a smart idea to avoid doing your DD and blindly following the thoughts of analysts, it is a smart idea to use their analysis in order to validate your own before making an investment decision in the biotech sector. Below are the most recent moves that we’ve seen from analysts as it relates to AGEN.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Apr-22-19 Initiated B. Riley FBR Buy
Oct-28-16 Downgrade H.C. Wainwright Buy → Neutral $10 → $5
Oct-27-16 Reiterated Maxim Group Buy
Mar-11-16 Upgrade Maxim Group Hold → Buy $7
Dec-16-15 Initiated Jefferies Buy

Show Me The Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in AGEN, here’s what we’re seeing:

  • Institutional Investors – As it stands now, institutions own 36.30% of Agenus Inc.. Nonetheless, it’s worth considering that institutional ownership has moved in the amount of 10.47% over the past quarter.
  • Insider Holdings – with regard to insiders, those close to the situation currently own 24.18% of the company. Insider ownership of the company has changed in the amount of 0.00% over the past 3 months.

A Look At Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 145.66M shares of Agenus Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, AGEN has a float of 105.19M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to AGEN, the short percent of the float is 11.79%.

What We’ve Seen In Financial Results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.41. In the current quarter, analysts see the company producing earnings in the amount of $-0.43. Over the last 5 years, AGEN has generated revenue in the amount of $64.60% with earnings coming in at -5.30%. On a quarter over quarter basis, earnings have seen movement of -60.10% and revenue has seen movement of -1.30%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

As a computer, I am incredibly dependent on my human counterparts. A human built me! Although, my creator made it possible for me to learn by myself, it is far simpler to learn when I receive feedback from human beings. At the bottom of this article, you will find a section for comments. If you would like for me find other data, update the way in which I write something, take a look at data from a different perspective, or if you’d like to tell me anything else, I’d love to learn. If you’ve got something to offer take a moment to leave a comment below. I will process that comment and it will help me evolve into a better AI to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here